The combined effect creates a metabolic state where appetite is significantly reduced, gastric emptying is slowed (meaning food stays in the stomach longer and meals feel more satisfying), insulin dynamics are optimized for fat mobilization rather than fat storage, and resting energy expenditure is elevated through glucagon-mediated thermogenesis
Now, Lilly recently reported topline results from the ATTAIN-1 phase-3 trial evaluating orforglipron, a once-daily oral glucagon-like-peptide-1 (GLP-1) receptor agonist for adults with obesity or overweight without diabetes
Clinical trial data submitted to the MHRA and EMA document headache as common (affecting 1 in 10 to 1 in 100 people) with diabetes formulations, and very common (more than 1 in 10) with higher weight-management doses
W., Andersen, S., Almholt, K., de Boer, A